SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a…
November 07, 2024
November 07, 2024
Lipocine: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Lipocine Inc. (LPCN) on Thursday reported a loss of $2.2 million in its third quarter….
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This…
November 06, 2024
Verastem: Q3 Earnings Snapshot
NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Wednesday reported a loss of $24 million in its third quarter. On a…
November 06, 2024
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
Completed rolling NDA submission for avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer in October 2024 Company seeking accelerated approval and…
November 05, 2024
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube,…
November 01, 2024
Verastem Oncology submits NDA for ovarian cancer treatment
Verastem initiated the rolling NDA submission in May. Credit: Jo Panuwat D via Shutterstock. Verastem Oncology has concluded the rolling submission of a new drug…
November 01, 2024
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys’ therapeutic option for women seeking permanent birth control ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) — Femasys Inc….
Recurrent low-grade serous ovarian cancer is a rare cancer with no FDA-approved treatments Company seeking accelerated approval and priority review of its NDA submission in…
October 31, 2024
Establishment Labs Announces Three-Year Mia Femtech Clinical Results at 9th World Symposium on Ergonomic Implants
NEW YORK, October 31, 2024–(BUSINESS WIRE)–Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in…
US·Associated PressA mother intentionally went over Niagara Falls with her 2 children, police sayA 33-year-old mother climbed over a safety rail and intentionally went over…
BOSTON, October 31, 2024–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management…